Centre for Research Excellence in Cervical Cancer Control (C4)

Grant number: 1135172 | Funding period: 2017 - 2023

Completed

Abstract

Cervical cancer remains common globally despite over 50 years of Pap testing. Australia led the world in HPV vaccination and in 2017 will be the first to deliver a national screening program based on HPV testing. Our CRE, led by cervical cancer prevention experts at CCNSW,VCS, and Kirby, will marry cross-disciplinary research and evaluation of HPV vaccination and screening to provide solid evidence about these new approaches with a view to ultimately reducing the global burden of this cancer.

Related publications (3)

How Does Transitioning to Primary Human Papillomavirus Screening Impact Colposcopy Services? Lessons from an Australian National Program

CJ Jennett, MA Smith, DA Machalek, F Sultana, KH Prang, T McDermott, CE Nightingale, CM Zammit, A Pagotto, NM Rankin, CDH Wrede, JML Brotherton

2025-01-01

Objective In 2017, Australian's National Cervical Screening Program changed from 2-yearly cytology to 5-yearly primary human papil..

Implementation of Australia's renewed cervical screening program: Preparedness of general practitioners and nurses

F Sultana, L Roeske, MJ Malloy, TL McDermott, M Saville, JML Brotherton

2020-01-01

The National Cervical Screening Program (NCSP) in Australia underwent major changes on December 1<sup>st</sup>, 2017. The program ..

Impact of HPV vaccination: Achievements and future challenges

JML Brotherton

2019-06-01

University of Melbourne Researchers

Suzanne Wark